A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms

Trial Profile

A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2015

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 27 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Aug 2014 Planned End Date changed from 1 Mar 2018 to 1 Feb 2018 as reported by ClinicalTrials.gov.
    • 14 Aug 2014 Planned primary completion date changed from 1 Jan 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top